文献速递产科

产后出血预防与治疗照护束的有效性:系统综述

Effectiveness of care bundles for prevention and treatment of postpartum hemorrhage: a systematic review.
PubMed 文献 · Am J Obstet Gynecol · 2024-02-07

本系统综述纳入22项研究,评估产后出血照护束的有效性与安全性。仅治疗束中E-MOTIVE干预有高确定性证据降低复合严重并发症(RR 0.40,95%CI 0.32-0.50)及输血等风险;加利福尼亚孕产妇质量照护协作组照护束可能降低严重孕产妇并发症(RR 0.64,95%CI 0.57-0.72),但证据确定性低。其他照护束设计在实施前需进一步有效性研究。

要点

  • E-MOTIVE干预有高确定性证据降低阴道分娩者产后出血相关复合严重并发症(RR 0.40)及输血风险。
  • 加利福尼亚孕产妇质量照护协作组照护束可能降低严重孕产妇并发症(RR 0.64),证据确定性低。
  • 其他照护束设计效果不确定,实施前需进一步有效性研究。

核心结论

  • E-MOTIVE干预改善阴道分娩女性的产后出血相关结局,加利福尼亚孕产妇质量照护协作组照护束可能降低严重孕产妇并发症。
  • 其他照护束设计在考虑实施前需进一步有效性研究。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase、Cochrane CENTRAL、Maternity and Infant Care Database、Global Index Medicus(从建库至2023年6月9日)及ClinicalTrials.gov和国际临床试验注册平台(近5年)。
  • 纳入评估产后出血相关照护束的同行评议研究;照护束定义为包含≥3个组分并集体、同时或快速连续实施的干预。
  • 纳入随机和非随机对照试验、中断时间序列及前后对照研究(对照或非对照),共22项研究纳入分析。
  • 使用RoB 2评估随机试验偏倚风险,ROBINS-I评估非随机研究;对照研究报告二分类结局的风险比和连续结局的均数差,证据确定性采用GRADE分级。
  • 非对照研究使用效应方向表并以叙述性方式总结结果。

主要发现

  • 仅预防束(2项研究):低确定性证据提示可能在减少失血量、住院时间、重症监护室停留时间及孕产妇健康状况方面有获益。
  • 仅治疗束(9项研究):高确定性证据显示E-MOTIVE干预降低复合严重并发症风险(风险比0.40;95%CI 0.32-0.50)及因出血、产后出血、严重产后出血的输血风险和平均失血量。
  • 1项非随机试验和7项非对照研究提示其他产后出血治疗束可能减少失血量和严重产后出血,但结果不确定。
  • 联合预防/治疗束(11项研究):低确定性证据显示加利福尼亚孕产妇质量照护协作组照护束可能降低严重孕产妇并发症(风险比0.64;95%CI 0.57-0.72)。
  • 10项非对照研究对其他类型照护束显示可能获益、无效或有害的结果不一;几乎所有非对照研究未采用适合单组前后比较的统计方法,应谨慎解读。

关键数值与推荐

  • 照护束定义:包含≥3个组分并集体、同时或快速连续实施的干预。
  • E-MOTIVE干预降低复合严重并发症:风险比0.40(95%CI 0.32-0.50),高确定性证据。
  • 加利福尼亚孕产妇质量照护协作组照护束降低严重孕产妇并发症:风险比0.64(95%CI 0.57-0.72),低确定性证据。

临床怎么用

  • E-MOTIVE干预可用于改善阴道分娩女性的产后出血相关结局,基于高确定性证据。
  • 加利福尼亚孕产妇质量照护协作组照护束可能降低严重孕产妇并发症,证据确定性低。
  • 其他照护束设计在考虑实施前需进一步有效性研究。

局限性

  • 仅预防束和联合预防/治疗束的证据确定性低。
  • 其他产后出血治疗束减少失血量和严重产后出血的结果不确定。
  • 10项非对照研究对其他类型照护束显示可能获益、无效或有害的结果不一。
  • 几乎所有非对照研究未采用适合单组前后比较的统计方法,应谨慎解读。
  • 其他照护束设计在考虑实施前需进一步有效性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Care bundles are a promising approach to reducing postpartum hemorrhage-related morbidity and mortality. We assessed the effectiveness and safety of care bundles for postpartum hemorrhage prevention and/or treatment. DATA SOURCES: We searched MEDLINE, Embase, Cochrane CENTRAL, Maternity and Infant Care Database, and Global Index Medicus (inception to June 9, 2023) and ClinicalTrials.gov and the International Clinical Trials Registry Platform (last 5 years) using a phased search strategy, combining terms for postpartum hemorrhage and care bundles. STUDY ELIGIBILITY CRITERIA: Peer-reviewed studies evaluating postpartum hemorrhage-related care bundles were included. Care bundles were defined as interventions comprising ≥3 components implemented collectively, concurrently, or in rapid succession. Randomized and nonrandomized controlled trials, interrupted time series, and before-after studies (controlled or uncontrolled) were eligible. METHODS: Risk of bias was assessed using RoB 2 (randomized trials) and ROBINS-I (nonrandomized studies). For controlled studies, we reported risk ratios for dichotomous outcomes and mean differences for continuous outcomes, with certainty of evidence determined using GRADE. For uncontrolled studies, we used effect direction tables and summarized results narratively. RESULTS: Twenty-two studies were included for analysis. For prevention-only bundles (2 studies), low-certainty evidence suggests possible benefits in reducing blood loss, duration of hospitalization, and intensive care unit stay, and maternal well-being. For treatment-only bundles (9 studies), high-certainty evidence shows that the E-MOTIVE intervention reduced risks of composite severe morbidity (risk ratio, 0.40; 95% confidence interval, 0.32-0.50) and blood transfusion for bleeding, postpartum hemorrhage, severe postpartum hemorrhage, and mean blood loss. One nonrandomized trial and 7 uncontrolled studies suggest that other postpartum hemorrhage treatment bundles might reduce blood loss and severe postpartum hemorrhage, but this is uncertain. For combined prevention/treatment bundles (11 studies), low-certainty evidence shows that the California Maternal Quality Care Collaborative care bundle may reduce severe maternal morbidity (risk ratio, 0.64; 95% confidence interval, 0.57-0.72). Ten uncontrolled studies variably showed possible benefits, no effects, or harms for other bundle types. Nearly all uncontrolled studies did not use suitable statistical methods for single-group pretest-posttest comparisons and should thus be interpreted with caution. CONCLUSION: The E-MOTIVE intervention improves postpartum hemorrhage-related outcomes among women delivering vaginally, and the California Maternal Quality Care Collaborative bundle may reduce severe maternal morbidity. Other bundle designs warrant further effectiveness research before implementation is contemplated.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Vogel JP, Nguyen PY, Ramson J, et al. Effectiveness of care bundles for prevention and treatment of postpartum hemorrhage: a systematic review. Am J Obstet Gynecol. 2024. PMID: 38336124. doi:10.1016/j.ajog.2024.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。